Customer Publication

A novel ROCK inhibitor: off-target effects of metformin

Authors: A. ÖZDEMİR et al.

Journal: Turkish Journal of Biology (2021)

Institution: Gazi University

Research Areas: Drug activity

Cell Lines: HeLa and MCF-7 (HeLa - cervical cancer cell line; MCF-7 breast cancer cell line)

Summary: Drug discovery and approval is a lengthy process. Thus in recent years, already approved drugs are tested against nontarget treatments. In this study, A. Özdemir with colleagues have tested two small molecules, metformin and tolbutamide, as Rho kinase (ROCK) inhibitors. Authors have shown that metformin has a potential as a ROCK inhibitor and could be used in treatments of various pathological conditions in which ROCK plays a role. HoloMonitor M4 was used to study cell morphology (cell area, thickness, volume, and irregularity) post-treatment with various concentrations of tolbutamide and metformin.

Keywords: HoloMonitor M4, cell morphology, connectivity MAP, Rho kinase, metformin, off-target effect, oral antidiabetics

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
Sweden
+46 46 38 60 80
info@phiab.se

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
USA
+1 617-963-5150
info@phiab.com

Invoicing

VAT: SE556542781101
faktura@phiab.se

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2